Tokyo Tape
Sign in
← Tohoku Chemical

Quarterly report · Q3

7446.TEDINET S100OW0Q
Period2021-10-01 → 2022-06-30
Filed2022-08-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 33
MetricValuePeriodScopeSource row
Revenue¥27.9bn2021-10-01 → 2022-06-30Cons.Net sales
Revenue¥36.2bn2020-10-01 → 2021-09-30Cons.Net sales (5-year summary)
Revenue¥27.2bn2020-10-01 → 2021-06-30Cons.Net sales
Operating income¥763m2021-10-01 → 2022-06-30Cons.Operating income
Operating income¥572m2020-10-01 → 2021-06-30Cons.Operating income
Ordinary income¥814m2021-10-01 → 2022-06-30Cons.Ordinary income
Ordinary income¥759m2020-10-01 → 2021-09-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥608m2020-10-01 → 2021-06-30Cons.Ordinary income
Profit before tax¥786m2021-10-01 → 2022-06-30Cons.Income before income taxes
Profit before tax¥612m2020-10-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)¥539m2021-10-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥517m2020-10-01 → 2021-09-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥428m2020-10-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income¥559m2021-10-01 → 2022-06-30Cons.Profit loss
Net income¥446m2020-10-01 → 2021-06-30Cons.Profit loss
Total assets¥15.0bnat 2022-06-30Cons.Assets
Total assets¥16.1bnat 2021-09-30Cons.Assets
Total assets¥16.2bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥8.5bnat 2022-06-30Cons.Liabilities
Total liabilities¥9.8bnat 2021-09-30Cons.Liabilities
Net assets / equity¥6.6bnat 2022-06-30Cons.Net assets
Net assets / equity¥6.3bnat 2021-09-30Cons.Net assets
Net assets / equity¥6.1bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.3bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥799mat 2021-09-30Cons.Cash and deposits
EPS (basic)¥596.992021-10-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥185.032022-04-01 → 2022-06-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥564.912020-10-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥467.382020-10-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥114.172021-04-01 → 2021-06-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio43.2%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio38.6%at 2021-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio37.3%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Otherother segmentsrevenue2021-10-01 → 2022-06-30¥318m
Otherother segmentsrevenue external2021-10-01 → 2022-06-30¥318m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2021-10-01 → 2022-06-30¥2.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2021-10-01 → 2022-06-30¥13.8bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2021-10-01 → 2022-06-30¥11.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2021-10-01 → 2022-06-30¥11.4bn
Total Of Reportable Segments And Otherssegment totalrevenue2021-10-01 → 2022-06-30¥27.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-10-01 → 2022-06-30¥27.9bn
Otherother segmentsrevenue2020-10-01 → 2021-06-30¥331m
Otherother segmentsrevenue external2020-10-01 → 2021-06-30¥331m
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue2020-10-01 → 2021-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Foodreportable segmentrevenue external2020-10-01 → 2021-06-30¥2.5bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue2020-10-01 → 2021-06-30¥13.4bn
jpcrp040300-q3r_E02810-000Pharmaceutical Productsreportable segmentrevenue external2020-10-01 → 2021-06-30¥13.4bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue2020-10-01 → 2021-06-30¥10.9bn
jpcrp040300-q3r_E02810-000Reagent For Clinical Testreportable segmentrevenue external2020-10-01 → 2021-06-30¥10.9bn
Total Of Reportable Segments And Otherssegment totalrevenue2020-10-01 → 2021-06-30¥27.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2020-10-01 → 2021-06-30¥27.2bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 381
ItemContextValueUnit
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02810-000PharmaceuticalProductsReportableSegmentsMember13441968000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02810-000ReagentForClinicalTestReportableSegmentsMember10907021000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E02810-000FoodReportableSegmentsMember2523727000JPY
Net salesPrior1YTDDuration_OtherReportableSegmentsMember331286000JPY
Net salesPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember27204004000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember－JPY
Net salesPrior1YTDDuration27204004000JPY
Gross profitPrior1YTDDuration_jpcrp040300-q3r_E02810-000PharmaceuticalProductsReportableSegmentsMember1066573000JPY
Gross profitPrior1YTDDuration_jpcrp040300-q3r_E02810-000ReagentForClinicalTestReportableSegmentsMember1028654000JPY
Gross profitPrior1YTDDuration_jpcrp040300-q3r_E02810-000FoodReportableSegmentsMember197847000JPY
Gross profitPrior1YTDDuration_OtherReportableSegmentsMember41503000JPY
Gross profitPrior1YTDDuration_TotalOfReportableSegmentsAndOthersMember2334579000JPY
Gross profitPrior1YTDDuration_ReconcilingItemsMember－JPY
Gross profitPrior1YTDDuration2334579000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02810-000PharmaceuticalProductsReportableSegmentsMember13757668000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02810-000ReagentForClinicalTestReportableSegmentsMember11386330000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E02810-000FoodReportableSegmentsMember2439249000JPY
Revenues from external customersCurrentYTDDuration_OtherReportableSegmentsMember318445000JPY
Revenues from external customersCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember27901693000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersCurrentYTDDuration27901693000JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02810-000PharmaceuticalProductsReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02810-000ReagentForClinicalTestReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_jpcrp040300-q3r_E02810-000FoodReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_OtherReportableSegmentsMember－JPY
Transactions with other segmentsCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember－JPY
Transactions with other segmentsCurrentYTDDuration_ReconcilingItemsMember－JPY
Transactions with other segmentsCurrentYTDDuration－JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E02810-000PharmaceuticalProductsReportableSegmentsMember13757668000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E02810-000ReagentForClinicalTestReportableSegmentsMember11386330000JPY
Net salesCurrentYTDDuration_jpcrp040300-q3r_E02810-000FoodReportableSegmentsMember2439249000JPY
Net salesCurrentYTDDuration_OtherReportableSegmentsMember318445000JPY
Net salesCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember27901693000JPY
Net salesCurrentYTDDuration_ReconcilingItemsMember－JPY
Net salesCurrentYTDDuration27901693000JPY
Gross profitCurrentYTDDuration_jpcrp040300-q3r_E02810-000PharmaceuticalProductsReportableSegmentsMember1209642000JPY
Gross profitCurrentYTDDuration_jpcrp040300-q3r_E02810-000ReagentForClinicalTestReportableSegmentsMember1150355000JPY
Gross profitCurrentYTDDuration_jpcrp040300-q3r_E02810-000FoodReportableSegmentsMember185015000JPY
Gross profitCurrentYTDDuration_OtherReportableSegmentsMember37236000JPY
Gross profitCurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember2582250000JPY
Gross profitCurrentYTDDuration_ReconcilingItemsMember－JPY
Gross profitCurrentYTDDuration2582250000JPY
Document title cover pageFilingDateInstant
Original text (Japanese)四半期報告書
Clause of stipulation cover pageFilingDateInstant
Original text (Japanese)金融商品取引法第24条の４の７第１項
Place of filing cover pageFilingDateInstant
Original text (Japanese)東北財務局長
Filing date cover pageFilingDateInstant2022-08-10
Quarterly accounting period cover pageFilingDateInstant
Original text (Japanese)第71期第３四半期(自 2022年４月１日 至 2022年６月30日)
Company name cover pageFilingDateInstant
Original text (Japanese)東北化学薬品株式会社
Company name in english cover pageFilingDateInstantTOHOKU CHEMICAL CO.,LTD.
Title and name of representative cover pageFilingDateInstant
Original text (Japanese)代表取締役社長　東　康之

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2021-09-30pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2021-09-30pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2020-10-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-10-01/2022-06-30pass
statement vs summary · revenueconsolidated 2020-10-01/2021-06-30pass
statement vs summary · revenueconsolidated 2021-10-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2021-09-30pass
statement vs summary · total assetsconsolidated 2022-06-30pass